Brief: Pfizer Says Litfulo Safety Profile In NSV Consistent With Alopecia Areata
02/10/2026 18:24
BRIEF-Pfizer Says Litfulo Safety Profile In NSV Consistent With Alopecia Areata Oct 2 (Reuters) - Pfizer Inc. PFE.N:
PFIZER’S LITFULO SIGNIFICANTLY IMPROVED FACIAL AND TOTAL BODY REPIGMENTATION IN PATIENTS WITH NONSEGMENTAL VITILIGO~
PFIZER - TO SUBMIT LITFULO PHASE 3 DATA TO FDA AND EMA
PFIZER - LITFULO SAFETY PROFILE IN NSV CONSISTENT WITH ALOPECIA AREATA; NO NEW SAFETY SIGNALS
Source text: ID:nBw2gHCtza
Further company coverage: PFE.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pfizer
See all newsBrief: Enanta Pharmaceuticals In Patent Infringement Action Against Pfizer
Brief: Edison Scientific Announces Agreement With Pfizer To Accelerate Research And Development
Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge (updated)
Corrected: Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Brief: Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma